LATEST NEWS
INTERESTED IN SUPPORTING US?
Support Oncoheroes by either donating through our trusted partners or investing directly in the company. Choose the option that fits you best and contribute today to our mission.
At Ally's request, the initial funding will support promising research by Oncoheroes. Focused entirely on developing new therapies for children with cancer, Oncoheroes is partnering with Hopp Children's Cancer Center Heidelberg (KiTZ) to test Onchoheroes' lead compound, Volasertib, with the hope of finding signs of efficacy in several types of pediatric cancers, including Rhabdomyosarcoma
In 2021, Fundación Olivares joined forces with Oncoheroes by funding the advancement of Volasertib. Once again, they demonstrate their commitment through a donation campaign that will be used to finance Volasertib’s trial.
Invest in Oncoheroes' investment round to finance Volasertib’s trial and become a partner in saving the lives of children with cancer.
Are you an accredited investor?
Invest in Oncoheroes' investment round to finance Volasertib’s trial and become a partner in saving the lives of children with cancer.
Every year
in pediatric cancer
HIDDEN HOPE
There is currently a portfolio of critical therapeutic targets in academic labs and a large amount of compounds in biopharmaceutical companies that hold the real promise for creating effective treatments against many forms of childhood cancer whose prognosis remains dismal.
Oncoheroes is rising up to reverse this situation by developing and commercializing lifesaving medicines. We intend to become the global leader in delivering new pediatric oncology drugs to the patients.
There is no time to wait!
Drug Discovery
Identify novel precision oncogenic targets to support the identification and validation of novel drug combinations.
Learn more →
Clinical Development
In-license clinical stage or near clinical stage assets that hold the potential to cure pediatric cancers.
Learn more →
Community
Partner with pharmaceutical industry, foundations and patient associations to support the development of novel therapies.
Learn more →
Let’s move the needle on new
therapies for childhood cancer